SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

PHIA

21.47

-0.46%↓

Sanofi SA

Затворен

СекторЗдравеопазване

92.06 2.59

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

89.74

Максимум

92.08

Ключови измерители

By Trading Economics

Приходи

1.4B

1.9B

Продажби

3B

11B

P/E

Средно за сектора

18.265

56.602

EPS

1.79

Дивидентна доходност

4.22

Марж на печалбата

17.65

Служители

82,878

EBITDA

2.2B

2.8B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+30.33% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

4.22%

2.45%

Следващи печалби

31.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-19B

111B

Предишно отваряне

89.47

Предишно затваряне

92.06

Настроения в новините

By Acuity

41%

59%

150 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Sanofi SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.05.2025 г., 11:29 ч. UTC

Придобивния, сливания и поглъщания

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- 2nd Update

5.05.2025 г., 09:09 ч. UTC

Придобивния, сливания и поглъщания

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- Update

5.05.2025 г., 07:25 ч. UTC

Придобивния, сливания и поглъщания

Erste Group to Buy Santander Assets in Poland for $7.91 Billion

15.05.2025 г., 11:04 ч. UTC

Пазарно говорене
Печалби

Spanish, Italian Banks Have Less Upside After Strong Run -- Market Talk

13.05.2025 г., 12:53 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Natwest's Reported Santander UK Interest Seems Surprising -- Market Talk

13.05.2025 г., 10:23 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Santander's Geographic Refocusing Can Lift Earning Estimates -- Market Talk

13.05.2025 г., 08:58 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Any Sale of Santander UK Would Need Strong Justification -- Market Talk

12.05.2025 г., 12:07 ч. UTC

Пазарно говорене

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

8.05.2025 г., 17:55 ч. UTC

Печалби

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

8.05.2025 г., 15:12 ч. UTC

Печалби

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

6.05.2025 г., 06:16 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Santander's Polish Business Disposal Is Attractive -- Market Talk

6.05.2025 г., 06:13 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Erste's Cash Deal for Santander Bank Polksa Seen as Positive -- Market Talk

5.05.2025 г., 14:11 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Erste Group Adds Exposure to Fast-Growing Polish Market, But Could Face Risk -- Market Talk

5.05.2025 г., 11:30 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Sale of Polish Business Strengthens Santander's Capital Position -- Market Talk

5.05.2025 г., 06:48 ч. UTC

Придобивния, сливания и поглъщания

Santander Intends to Take Full Ownership of Santander Consumer Bank Polska

5.05.2025 г., 06:48 ч. UTC

Придобивния, сливания и поглъщания

Santander Will Own 13% of Santander Polska Following Transaction

5.05.2025 г., 06:47 ч. UTC

Придобивния, сливания и поглъщания

Santander, Erste Enter Cooperation in Corporate & Investment Banking, Payments

5.05.2025 г., 06:46 ч. UTC

Придобивния, сливания и поглъщания

Santander Expects EUR2B Net Capital Gain From Deal

5.05.2025 г., 06:46 ч. UTC

Придобивния, сливания и поглъщания

Erste Group Says Profitability Is Set to Improve Significantly After Deal

5.05.2025 г., 06:45 ч. UTC

Придобивния, сливания и поглъщания

Erste Group Targets Return to Current Dividend Payout Range of 40-50% From 2026

5.05.2025 г., 06:45 ч. UTC

Придобивния, сливания и поглъщания

Erste Group to Reduce 2025 Dividend Payout to Maximum of 10% of Net Profit

5.05.2025 г., 06:45 ч. UTC

Придобивния, сливания и поглъщания

Erste Group: Dividend for 2024 Remains Unchanged at EUR3 a Share

5.05.2025 г., 06:44 ч. UTC

Придобивния, сливания и поглъщания

Erste Group to Temporarily Reduce Dividend Payout

5.05.2025 г., 06:43 ч. UTC

Придобивния, сливания и поглъщания

Erste Group to Cancel Planned EUR700M Buyback

5.05.2025 г., 06:42 ч. UTC

Придобивния, сливания и поглъщания

Erste Group Will Fund the Acquisition Exclusively From Internal Resources

5.05.2025 г., 06:40 ч. UTC

Придобивния, сливания и поглъщания

Santander Says It Plans to Distribute EUR3.2B Through Buybacks

5.05.2025 г., 06:39 ч. UTC

Придобивния, сливания и поглъщания

Erste Group to Buy 49% of Santander Polska's for PLN584 a Share

5.05.2025 г., 06:38 ч. UTC

Придобивния, сливания и поглъщания

Erste Group to Buy 49% Stake in Poland Unit of Banco Santander

5.05.2025 г., 06:37 ч. UTC

Придобивния, сливания и поглъщания

Erste Group to Become No. 3 Bank in Poland Through Deal

5.05.2025 г., 06:36 ч. UTC

Придобивния, сливания и поглъщания

Erste Group Also Acquires 50% in Asset Management Firm Santander TFI for EUR200M

Сравнение с други в отрасъла

Ценова промяна

Sanofi SA Прогноза

Ценова цел

By TipRanks

30.33% нагоре

12-месечна прогноза

Среден 115.786 EUR  30.33%

Висок 127 EUR

Нисък 95 EUR

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Sanofi SA през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

15 ratings

11

Купи

4

Задържане

0

Продай

Техническа оценка

By Trading Central

91.3 / 96.1Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

150 / 382 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.